EXAS vs NGVT · rev $2.76B vs rev $572.1M
EXACT Sciences Corporation (EXAS) versus Ingevity Corp (NGVT) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Ingevity Corp (NGVT) is a specialty chemicals company listed on NYSE.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported NGVT revenue for 2026-06-30 was $572.1M. Net income was $95.1M. NGVT currently screens at market cap $2.52B.
EXAS currently screens at market cap $20.03B. NGVT currently screens at market cap $2.52B.
Not investment advice. Open the EXAS and NGVT stock pages for the full models.
Not investment advice.